Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Kobold Capital is an investment firm founded in Australia, focusing on life sciences and emerging medical technologies. Established to identify and capitalize on high-value opportunities, the firm operates in both public and private life sciences sectors. Kobold Capital emphasizes rigorous scientific and commercial diligence to improve outcomes in a sector known for its high failure rate.
The firm currently manages a portfolio of four companies and engages in investments across various stages, including pre-seed, seed, Series A, Series B, Series C, and pre-IPO. Kobold Capital's approach combines extensive experience in scientific, intellectual property (IP), and capital markets, allowing them to add significant value to their portfolio companies.
With a global investment strategy, Kobold Capital seeks to leverage its expertise to enhance the growth potential of its investments. The firm is committed to identifying high-impact opportunities that align with its investment thesis, focusing on sectors such as biotech, healthcare, and artificial intelligence.
Kobold Capital invests primarily in life sciences, greentech, deep tech, and artificial intelligence. The firm targets investments that exhibit potential for exponential growth or are nearing significant value inflection points. Their investment strategy encompasses both private and public investments, including pre-IPO and early-stage seed rounds, with a strong emphasis on high-impact opportunities.
The firm looks for companies with differentiated science or IP, credible management teams, and defined milestones that facilitate rapid value creation. Kobold Capital's investment criteria include a thorough assessment of the commercial landscape, IP position, management quality, and competitive dynamics. This diligence ensures that they identify companies capable of navigating the high-risk life sciences sector effectively.
Geographically, Kobold Capital maintains a global focus, allowing them to tap into diverse markets and innovative startups. Their selective investment approach aims to find high-growth companies or those approaching meaningful value inflection points, ensuring alignment with their strategic goals.
Kobold Capital has a notable track record of investing in early-stage life sciences and technology companies. Their current portfolio includes:
These companies exemplify Kobold Capital's commitment to investing in high-impact sectors, particularly in life sciences and technology, where they can apply their expertise to drive growth and innovation.
Dr. Damian Slizys - Principal / Managing Director. Dr. Slizys is a registered patent attorney with over 20 years of experience in intellectual property. He has previously served as an equity partner at a top-tier patent attorney firm and as in-house IP director for a life sciences company. He is also the Managing Director of Kobold Capital.
Dr. Julian Chick - Principal. Dr. Chick has more than 25 years of experience in biotechnology and medical technology, including investment banking and life sciences portfolio management. He previously managed a public life sciences portfolio at BCIF, achieving an average return of 32% per annum over four years and has been involved in 16 life-science startups.
Ryder Widdowson - Principal. Widdowson has 30 years of experience in financial services and has served as the responsible manager of two Australian Financial Services License holders. His expertise spans investor expectations, governance, and long-term investment structures.
As of April 2026, Kobold Capital continues to actively invest in early-stage life sciences and technology companies. Their recent focus has been on identifying high-value opportunities in both public and private sectors, aligning with their investment thesis.
The firm has highlighted its commitment to rigorous scientific and commercial diligence, which is crucial in a sector characterized by high failure rates. This approach positions Kobold Capital as a significant player in the life sciences investment space.
What are Kobold Capital's investment criteria?
Kobold Capital focuses on life sciences, greentech, deep tech, and artificial intelligence. They seek companies with differentiated science or IP, credible management, and defined milestones that facilitate rapid value creation.
How can founders pitch to Kobold Capital?
Founders can reach out through Kobold Capital's website for investment inquiries. They should prepare a detailed pitch that highlights their technology, market potential, and team credentials.
What makes Kobold Capital different from other VCs?
Kobold Capital emphasizes rigorous scientific and commercial diligence, focusing on high-impact opportunities in life sciences and emerging technologies. Their team has extensive experience in scientific, IP, and capital markets, allowing them to add significant value to portfolio companies.
What is Kobold Capital's geographic focus?
The firm has a global investment strategy, allowing them to identify and invest in innovative startups across various markets.
What stages of investment does Kobold Capital engage in?
Kobold Capital invests across multiple stages, including pre-seed, seed, Series A, Series B, Series C, and pre-IPO, targeting high-growth opportunities.
What kind of support do portfolio companies receive?
Kobold Capital actively engages with its portfolio companies, leveraging its team's expertise in scientific, IP, and capital markets to enhance growth and value creation.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.